Table 2 -.

Determination of optimal threshold for absolute lymphocyte count (ALC) for prediction of clinical outcomes

Measure	ALC Cutoff	Training Set	Test Set	Bootstrap (Test Set)
	(/μL)	HR (95% CI)	HR (95% CI)	HR mean (95% CI)	Power
Overall survival
ALC @ day 30	250	0.59 (0.45–0.78)	0.57 (0.37–0.89)	0.58 (0.34–0.90)	0.69
ALC @ day 60	300	0.42 (0.32–0.56)	0.43 (0.27–0.67)	0.43 (0.25–0.71)	0.93
ALC @ day 90	500	0.53 (0.39–0.71)	0.59 (0.37–0.93)	0.59 (0.35–0.91)	0.64
ALC @ day 120	420	0.50 (0.35–0.72)	0.36 (0.21–0.63)	0.38 (0.20–0.65)	0.93
ALC @ day 180	500	0.46 (0.30–0.72)	0.26 (0.11–0.59)	0.27 (0.01–0.63)	0.88
Relapse-free survival
ALC @ day 30	250	0.61 (0.47–0.79)	0.57 (0.37–0.88)	0.58 (0.35–0.87)	0.72
ALC @ day 60	280	0.49 (0.37–0.66)	0.51 (0.33–0.79)	0.52 (0.30–0.83)	0.85
ALC @ day 90	500	0.57 (0.43–0.76)	0.57 (0.37–0.89)	0.57 (0.34–0.86)	0.73
ALC @ day 120	420	0.53 (0.37–0.75)	0.37 (0.22–0.64)	0.38 (0.21–0.64)	0.94
ALC @ day 180	500	0.47 (0.31–0.72)	0.22 (0.09–0.50)	0.23 (0.08–0.51)	0.93
Relapse
ALC @ day 30	220	0.67 (0.47–0.94)	0.81 (0.43–1.54)	0.87 (0.45–1.55)	0.11
ALC @ day 180	750	0.55 (0.33–0.93)	0.67 (0.28–1.62)	0.76 (0.27–1.69)	0.16
Non-relapse mortality
ALC @ day 30	250	0.50 (0.33–0.76)	0.27 (0.14–0.51)	0.28 (0.13–0.50)	0.98
ALC @ day 60	450	0.17 (0.10–0.29)	0.18 (0.09–0.38)	0.19 (0.07–0.36)	>0.99
ALC @ day 90	500	0.28 (0.17–0.46)	0.25 (0.12–0.53)	0.26 (0.10–0.50)	0.96
ALC @ day 120	415	0.38 (0.22–0.66)	0.18 (0.07–0.49)	0.20 (0.05–0.50)	0.94
ALC @ day 180	500	0.35 (0.18–0.70)	0.07 (0.01–0.40)	*

HR: Hazard ratio

^*:Many of the bootstrapped samples for ALC on day 180 did not have non-relapse mortality events in one of the ALC groups, therefore, the results for this category were deemed questionable and not reported